Aanastra Inc (formerly Aadigen Inc) is a start-up biopharmaceutical company focused on treating cancer using its novel RNA therapeutics strategy to target aberrant Tumor Suppressor Genes and Oncogenes. The technology driving Aanastra’s approach is based on proprietary RNA combined with proprietary peptides that are able to target various tissues and tumors in vivo unlike commonly used strategies for RNA delivery including viral and lipid-based methods. Aanastra’s strategy for aberrant Tumor Suppressor Rescue using proprietary mRNA and gene editing of mutated Oncogenes have shown remarkable antitumor effects in animal models of various cancers that have mutated P53, KRAS or BRCA1. The utility of Aanastra’s technology has also been demonstrated outside of cancer in animal models of hemophilia A to normalize Factor VIII levels and in cholesterol lowering applications by targeting PCSK9. Aanastra (Los Angeles, CA) works closely with its sister company Divincell SAS (Nimes, France) in the development of its RNA therapeutics. More information on the Company's strategy is available on the Aanastra website at www.aanastra.com
External link for Aanastra Inc
Executive Chairman, Founder and former CEO Aadi Bioscience Inc; Founder and Chairman, Aanastra Inc
Aanastra will be presenting its RNA Therapeutic work at AACR. I’m happy to share our press release that went out this morning April 3, 2024. https://lnkd.in/gAUebMPk
Aanastra will be at AACR. I’m happy to share our press release that went out this morning April 3, 2024. https://lnkd.in/gtHP-UKC